Who gets what?
In the event of commercialisation, the University of Oslo and the health trusts under the South-Eastern Norway Regional Health Authority will give a third of all net income to the employee, a third to the employer and a third to Inven2. This principle is called ‘the three-way model’.
The employer’s part is often given to the inventor’s research environment, while Inven2’s part is invested in the development of new innovation projects. The three-way model is a generous scheme for researchers compared with similar models in the private business sector.
In the event of a company formation, a licence agreement, which transfers the rights of commercialisation of the technology to the new company, will be drawn up. The investors receive a third of the net income from this licence agreement, and they will also have the opportunity to buy a third of Inven2’s initial share capital.
